|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.39 USD | +8.59% |
|
+12.10% | +141.74% |
| Apr. 22 | Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating | MT |
| Apr. 22 | Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating | MT |
Ocugen, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 6.04 million compared to USD 2.49 million a year ago. Net loss was USD 63.08 million compared to USD 86.8 million a year ago.
Basic loss per share from continuing operations was USD 0.26 compared to USD 0.4 a year ago. Diluted loss per share from continuing operations was USD 0.26 compared to USD 0.4 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +141.74% | 329M | |
| +1.77% | 42.75B | |
| +47.70% | 41.61B | |
| +12.24% | 41.34B | |
| -8.83% | 26.59B | |
| +7.44% | 25.49B | |
| -23.01% | 18.12B | |
| +30.56% | 12.24B | |
| -1.82% | 11.76B | |
| +8.35% | 11B |
OCUGEN, INC. 
